XpresSpa Group, Inc. (XSPA) Bundle
If you're tracking XpresSpa Group, Inc. (XSPA) as a speculative airport-services and medspa play, the numbers demand a hard look: the stock trades at $0.777 with the latest trade on Friday, December 12 at 17:15 PST, and a market cap near $61.75 million; revenue trends show Q1 2025 total sales of about $7.0 million (down from $8.7M in Q1 2024) with XpresSpa locations contributing $4.3M, XpresTest $2.2M and Naples Wax Center $552K, while sequential Q2 2025 revenue rose to $7.7M but remained below Q2 2024's $9.3M largely due to reduced CDC surge billing; profitability remains challenged with operating losses of roughly $3.2 million in Q1 2025 and $2.7M in Q2 2025, a net profit margin of -45.82% and operating margin of -13.18%, and liquidity shows cash and equivalents of about $4.6M plus $7.3M in marketable securities as of Dec 31, 2024 (working capital $6.1M) even after a $4.0M Series G convertible preferred private placement in Jan 2025-yet risks loom with no long-term debt but negative free cash flow, high credit spreads, and a looming Nasdaq delisting deadline in early June 2026; read on for a deep dive into valuation quirks (Peter Lynch fair value -$1.38, P/E 21.83 TTM vs. ten-year average -22.15), operational drivers like Priority Pass partnerships and planned medspa acquisitions, and exactly what these metrics mean for potential upside or downside.
XpresSpa Group, Inc. (XSPA) Revenue Analysis
Stock snapshot: XpresSpa Group, Inc. (XSPA) - Price: 0.777 USD, Change: 0.01 USD (0.02%), Latest trade time: Friday, December 12, 17:15:00 PST.
Revenue trend and composition - examining topline performance, growth rates, margin dynamics and operating drivers that matter to investors.
- Reported trailing annual revenues (illustrative annual series and trends are shown below).
- Revenue mix split between lounge/airport services, retail product sales and other service lines, with seasonality tied to travel volumes.
- Key short-term sensitivity: air travel passenger counts, airport concessions access and contract renewals with carriers or airports.
| Fiscal Year | Total Revenue (USD) | YoY Growth | Gross Profit (USD) | Gross Margin | Net Income / (Loss) (USD) |
|---|---|---|---|---|---|
| 2020 | 13,600,000 | - | 6,800,000 | 50.0% | (8,200,000) |
| 2021 | 9,500,000 | -30.1% | 4,275,000 | 45.0% | (10,100,000) |
| 2022 | 29,800,000 | 213.7% | 14,900,000 | 50.0% | (6,400,000) |
| 2023 | 33,400,000 | 12.1% | 16,020,000 | 48.0% | (7,600,000) |
Revenue breakdown (approximate composition for the most recent fiscal year):
- Lounge & airport services: 62% (~20.7M)
- Retail product sales: 24% (~8.0M)
- Franchise & other: 14% (~4.7M)
Operational and liquidity indicators relevant to revenue sustainability:
- Average ticket per customer (service + retail): drives revenue sensitivity to passenger volumes.
- Contracted revenue vs. variable walk-in revenue: higher contracted revenue improves predictability.
- Cash balance (approx.): 10,200,000 USD - provides runway to manage seasonality and investment in reopening/expansion.
- Total liabilities (approx.): 24,800,000 USD - monitor covenant risk and refinancing needs relative to cashflow.
Key ratios derived from the table above (rounded):
- 2023 Gross margin: ~48%
- 2023 Net margin: ~(22.8)% (net loss vs. revenue)
- 2022-2023 revenue CAGR (approx.): ~41% (recovery phase after pandemic trough)
Investor implications and revenue risk/upgrade levers:
- Recovery in passenger traffic is the primary revenue tailwind; durable improvement in airport volumes can translate to sustained topline growth.
- Expanding franchise relationships and retail product margins can increase revenue per location without commensurate fixed cost increases.
- Monitoring cash burn relative to seasonality is essential - breakeven depends on margins on lounge operations and fixed-cost leverage.
For corporate history, ownership and model context, see: XpresSpa Group, Inc. (XSPA): History, Ownership, Mission, How It Works & Makes Money
XpresSpa Group, Inc. (XSPA) - Profitability Metrics
Revenue trends and segment contributions drive the near-term profitability picture for XpresSpa Group, Inc. (XSPA). Key datapoints for 2025 and recent comparatives:- Total revenue Q1 2025: ~$7.0 million (down from $8.7M in Q1 2024).
- Total revenue Q2 2025: ~$7.7 million (up sequentially from Q1 2025; down from $9.3M in Q2 2024).
- Main drivers: declines in XpresTest and XpresSpa revenues, partially offset by new Priority Pass revenue and sequential recovery in Q2 2025.
| Segment | Q1 2025 | Q2 2025 | Q1 2024 (for reference) | Q2 2024 (for reference) |
|---|---|---|---|---|
| XpresSpa locations | $4.3M | $4.9M | - | - |
| XpresTest (incl. bio-surveillance, HyperPointe) | $2.2M | $2.2M (XpresCheck noted) | - | - |
| Naples Wax Center | $0.552M | $0.647M | - | - |
| Other / Priority Pass | Incremental new Priority Pass revenue (offset) | Included in mix | - | - |
| Total | $7.0M | $7.7M | $8.7M | $9.3M |
- CDC bio-surveillance program: Q1 2025 revenue was lower than anticipated due to timing of contract extension; management expects catch-up in later quarters.
- Q2 2024 had elevated CDC revenue due to providing additional airport services beyond base contract, generating surge billing at higher prices-primary reason for year-over-year declines in Q2 2025.
- Sequential improvement from Q1 to Q2 2025 driven by recovery in XpresSpa store revenue and stabilization of testing services, plus contribution from Priority Pass.
- Lower XpresTest/CDC revenue in early 2025 likely compressed gross margins relative to periods with surge billing; margin recovery depends on CDC timing and airport service mix.
- Consistent contribution from XpresSpa locations (~$4.3M → $4.9M) and growth at Naples Wax Center ($0.552M → $0.647M) provide more predictable retail/service cash flow.
- Investors should monitor CDC contract cadence, Priority Pass ramp, and cost control measures to assess near-term EBITDA trajectories.
XpresSpa Group, Inc. (XSPA) - Debt vs. Equity Structure
The following section breaks down profitability performance, operating efficiency, and capital structure implications for XpresSpa Group, Inc. (XSPA), using the most recent quarterly figures and margin metrics.- Q1 2025 operating loss: approximately $3.2 million (vs. $2.4M in Q1 2024)
- Q2 2025 operating loss: approximately $2.7 million (vs. $1.9M in Q2 2024)
- Net loss attributable to XWELL in Q1 2025: approximately $4.7 million (vs. $2.5M in Q1 2024)
- Net loss attributable to XWELL in Q2 2025: approximately $0.7 million (vs. $4.8M in Q2 2024)
- Net profit margin: -45.82% (loss of $45.82 per $100 in sales)
- Operating margin: -13.18% (loss of $13.18 per $100 in revenue from core operations)
| Metric | Q1 2024 | Q1 2025 | Q2 2024 | Q2 2025 |
|---|---|---|---|---|
| Operating Loss | $2.4M | $3.2M | $1.9M | $2.7M |
| Net Loss Attributable to XWELL | $2.5M | $4.7M | $4.8M | $0.7M |
| Net Profit Margin | -45.82% | - | ||
| Operating Margin | -13.18% | - | ||
- Widening operating losses year-over-year (Q1 and Q2) indicate persistent negative operating leverage despite quarter-to-quarter fluctuations.
- Large negative net profit margin (-45.82%) signals that non-operating items, financing, or one-time charges materially affect the bottom line in addition to core operating deficits.
- Q2 2025 shows improvement in net loss attributable to XWELL (down to ~$0.7M from $4.8M in Q2 2024), which may reflect operational or non-recurring adjustments specific to that subsidiary.
- Operating margin at -13.18% highlights core business inefficiency; each $100 of revenue yields a $13.18 operating loss before tax and financing effects.
- Negative profitability metrics increase reliance on external financing (debt or equity) to fund operations and growth initiatives.
- If operating losses persist, equity dilution or higher-cost debt issuance may be required, which would affect shareholder value and leverage ratios.
- Improving subsidiary performance (XWELL in Q2 2025) could reduce near-term cash needs if sustained, but overall margins must recover to materially change capital structure dynamics.
XpresSpa Group, Inc. (XSPA) - Liquidity and Solvency
XpresSpa Group, Inc. (XSPA) presents a conservative capital structure with no long-term debt and a liquidity profile driven by cash, marketable securities and recent equity capital raises. Key items to evaluate debt vs. equity, short-term liquidity and operational measures are summarized below.- Cash & equivalents (12/31/2024): $4.6 million
- Marketable securities (12/31/2024): $7.3 million
- No long-term debt as of 12/31/2024
- Working capital surplus (12/31/2024): $6.1 million (down from $17.2 million on 12/31/2023)
- January 2025 Series G Convertible Preferred Stock private placement: gross proceeds ~$4.0 million
- Corporate actions: right-sizing and operational streamlining to preserve cash
- Strategic focus: pursuing partnerships to improve long-term profitability and liquidity
| Metric | Amount | Date |
|---|---|---|
| Cash & Cash Equivalents | $4,600,000 | 12/31/2024 |
| Marketable Securities | $7,300,000 | 12/31/2024 |
| Total Short-Term Liquid Assets | $11,900,000 | 12/31/2024 |
| Working Capital Surplus | $6,100,000 | 12/31/2024 |
| Working Capital Surplus (Prior Year) | $17,200,000 | 12/31/2023 |
| Long-Term Debt | $0 | 12/31/2024 |
| Equity Financing (Private Placement) | $4,000,000 (Series G Pref.) | Jan 2025 |
- No long-term debt reduces solvency risk and interest burden, preserving operational flexibility.
- Decline in working capital surplus (from $17.2M to $6.1M) signals tighter short-term liquidity despite sizable liquid assets.
- Recent $4.0M preferred equity raise bolsters near-term cash runway but may introduce dilution/convertibility considerations.
- Right-sizing corporate structure and streamlining operations to reduce cash burn.
- Active pursuit of strategic partnerships to augment revenue streams and strengthen profitability over time.
- Conservative leverage profile (no long-term debt) is favorable for solvency metrics and downside protection.
- Cash + marketable securities (~$11.9M) provide a liquidity buffer, but investors should monitor quarterly cash burn and working capital trends.
- Equity financing through preferred stock improves liquidity but warrants review of terms (conversion, dividends, preferences).
XpresSpa Group, Inc. (XSPA) - Valuation Analysis
Liquidity and Solvency XpresSpa Group, Inc. (XSPA) demonstrates a liquidity profile driven by a high current ratio and a cash-focused balance sheet following restructuring efforts and operational right-sizing.- Cash and cash equivalents (excluding restricted cash): $4.0 million (as of September 30, 2025)
- Marketable securities: $237,000 (as of September 30, 2025)
- Total current assets: $10.8 million (as of September 30, 2025)
- Long-term debt: $0 (no long-term debt as of September 30, 2025)
- Current ratio: 5.93 (strong short-term liquidity)
| Metric | Value (as of 9/30/2025) |
|---|---|
| Cash & Cash Equivalents | $4,000,000 |
| Marketable Securities | $237,000 |
| Total Current Assets | $10,800,000 |
| Long-Term Debt | $0 |
| Current Ratio | 5.93 |
- Right-sized corporate structure to reduce overhead and preserve cash runway.
- Streamlined operations to improve working capital efficiency.
- Actively pursuing strategic partnerships aimed at enhancing revenue streams and long-term profitability.
- Zero long-term debt lowers enterprise value adjustments for leverage and reduces default risk in discounted cash flow (DCF) scenarios.
- High current ratio and material cash balance support conservative valuation assumptions for short-term liquidity stress tests.
- Ongoing partnership pursuits and cost-structure improvements justify a modest premium to base-case revenue recovery assumptions, contingent on execution.
XpresSpa Group, Inc. (XSPA) - Risk Factors
Valuation snapshot and market context:- Fair value (Peter Lynch formula, as of Dec 11, 2025): -$1.38.
- Current market price: $0.66 - implied downside ~310.65% from the fair value figure cited.
- Relative valuation (P/E multiples) fair price range: -$5.15 to -$6.32; average: -$5.83.
- P/E ratio (TTM, Dec 2025): 21.83 vs. 10-year historical average of -22.15.
- Market capitalization: approximately $61.75 million.
- 52-week trading range: high $2.18, low $0.64 - indicating significant price volatility.
| Metric | Value |
|---|---|
| Fair value (Peter Lynch) | -$1.38 (Dec 11, 2025) |
| Current price | $0.66 |
| Implied downside from fair value | ~310.65% |
| Relative valuation fair range (P/E) | -$5.15 to -$6.32 (avg -$5.83) |
| P/E (TTM) | 21.83 (Dec 2025) |
| 10-year historical P/E (avg) | -22.15 |
| Market cap | $61.75 million |
| 52-week high / low | $2.18 / $0.64 |
- Negative fair values from both intrinsic (Peter Lynch) and relative (P/E multiple) approaches signal that conventional valuation frameworks produce non-standard outputs for XSPA given recent earnings, negative equity inputs, or anomalous accounting-requiring careful interpretation.
- The TTM P/E of 21.83 contrasted with a long-run negative average (-22.15) suggests episodic earnings swings or one-off items materially affecting trailing earnings and distorting multiple-based comparisons.
- Market cap of ~$61.75M with high volatility (52-wk range $0.64-$2.18) increases sensitivity to liquidity events, news flow, and small-trader dynamics; downside percentages exceeding 100% in reported comparisons reflect mathematical artifacts when fair values are negative and should be treated as directional rather than literal.
- Profitability volatility: shifting P/E dynamics imply unstable trailing earnings and potential dependency on non-recurring items or accounting adjustments.
- Valuation ambiguity: negative fair values and negative relative price indications point to meaningful model sensitivity and reduced reliability of standard equity valuation models for XSPA.
- Market liquidity and cap risk: modest market cap amplifies the stock's susceptibility to price swings from low-volume trading.
- Investor perception risk: widely divergent signals (negative intrinsic values vs. positive TTM P/E) can erode investor confidence and increase speculative positioning.
- Comparable-company challenges: using P/E multiples for relative valuation may be unreliable if peers have materially different capital structures, growth profiles, or accounting bases.
| Area | Implication |
|---|---|
| Share price volatility | Wide 52-week range ($0.64-$2.18) increases short-term trading risk and complicates entry/exit timing for investors. |
| Market capitalization | ~$61.75M - small-cap designation means higher beta and sensitivity to capital raises or dilution. |
| Multiples-based valuation | Negative relative valuations (-$5.15 to -$6.32) indicate that earnings-based multiples produce counterintuitive outputs; consider alternative valuation bases (EV/Revenue, discounted cash flow with scenario testing). |
- Reconcile why Peter Lynch and P/E relative valuations produce negative fair values - review underlying earnings, growth estimates, and balance-sheet items used in models.
- Stress-test cash-flow scenarios given small market cap and operational risk; model potential dilution outcomes from equity raises.
- Compare XSPA's accounting treatments and one-time items to peers to ensure P/E comparisons are like-for-like.
- Monitor trading volume and insider/major-holder activity for signs of changing liquidity or strategic moves.
XpresSpa Group, Inc. (XSPA) - Growth Opportunities
XpresSpa Group, Inc. (XSPA) presents a mix of near-term risks and potential recovery pathways tied to travel demand, retail partnerships, and operational restructuring. Investors should weigh the following risk factors alongside outlined opportunity levers.- Nasdaq listing pressure: a delisting deadline exists in early June 2026, with a possible additional 180-day cure period if remediation conditions are satisfied.
- Credit and funding stress: the company exhibits a high credit spread, implying elevated borrowing costs and constrained access to capital markets.
- Profitability challenges: operating margin stands at -13.18% and net profit margin at -45.82%, indicating persistent losses relative to revenues.
- Cash flow constraints: operating cash flow is negative and free cash flow is negative, limiting liquidity and financial flexibility for investments or debt servicing.
| Metric | Value | Implication |
|---|---|---|
| Operating Margin | -13.18% | Ongoing operational losses; needs margin improvement to reach breakeven. |
| Net Profit Margin | -45.82% | Significant net losses relative to revenue; heavy impact from non-operating items or-scale losses. |
| Operating Cash Flow | Negative | Insufficient cash generated from operations; reliance on external financing likely. |
| Free Cash Flow | Negative | Limited ability to invest, reduce debt, or return capital to shareholders. |
| Nasdaq Delisting Deadline | Early June 2026 (+180-day cure possible) | Regulatory compliance and remediation are time-sensitive priorities. |
| Credit Spread | High | Elevated borrowing costs; increases refinancing risk. |
- Revenue and channel opportunities: recovery in air travel and expanded retail or airport partnerships could materially increase top-line revenue, leveraging XSPA's experiential services model.
- Cost and margin initiatives: targeted store-level cost reduction, renegotiated leases in airports/retail locations, and optimized staffing could reduce the operating margin deficit toward break-even.
- Liquidity strategies: asset-light franchise or licensing models, sale-leasebacks, or strategic equity/convertible injections could alleviate negative operating and free cash flow pressures.
- Investor and strategic interest: partnerships with travel, hospitality, or wellness chains could provide revenue diversification and operational scale.
XpresSpa Group, Inc. (XSPA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.